JP2016530311A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530311A5 JP2016530311A5 JP2016542052A JP2016542052A JP2016530311A5 JP 2016530311 A5 JP2016530311 A5 JP 2016530311A5 JP 2016542052 A JP2016542052 A JP 2016542052A JP 2016542052 A JP2016542052 A JP 2016542052A JP 2016530311 A5 JP2016530311 A5 JP 2016530311A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- mandelate
- atrasentan
- mandelic acid
- atlasentan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 12
- 229950010993 atrasentan Drugs 0.000 claims 10
- 239000002904 solvent Substances 0.000 claims 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 9
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 claims 9
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical group OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 claims 7
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 6
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims 6
- 229960002510 mandelic acid Drugs 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 5
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 229940109239 creatinine Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- -1 atrasentan mandelate salt Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361877101P | 2013-09-12 | 2013-09-12 | |
| US61/877,101 | 2013-09-12 | ||
| US14/133,297 US8962675B1 (en) | 2013-09-12 | 2013-12-18 | Atrasentan mandelate salts |
| US14/133,297 | 2013-12-18 | ||
| PCT/US2014/054888 WO2015038571A1 (en) | 2013-09-12 | 2014-09-10 | Atrasentan mandelate salts for the treatement of kidney diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016530311A JP2016530311A (ja) | 2016-09-29 |
| JP2016530311A5 true JP2016530311A5 (enExample) | 2017-09-28 |
Family
ID=52472936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542052A Pending JP2016530311A (ja) | 2013-09-12 | 2014-09-10 | 腎臓疾患治療のためのアトラセンタン・マンデル酸塩 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8962675B1 (enExample) |
| EP (2) | EP3044222B1 (enExample) |
| JP (1) | JP2016530311A (enExample) |
| CN (1) | CN105745204A (enExample) |
| AU (1) | AU2014318924A1 (enExample) |
| CA (1) | CA2923627C (enExample) |
| CL (1) | CL2016000583A1 (enExample) |
| MX (1) | MX2016003065A (enExample) |
| WO (1) | WO2015038571A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2016103764A (ru) * | 2013-07-08 | 2017-08-11 | Эббви Инк. | Стабилизированные фармацевтические лекарственные формы, содержащие атрасентан |
| CN105905245B (zh) * | 2016-06-03 | 2018-12-25 | 青岛北海船舶重工有限责任公司 | 用于水面无人艇布放回收的吊笼 |
| CN116173014A (zh) | 2019-12-17 | 2023-05-30 | 奇努克医疗公司 | 用阿曲生坦治疗IgA肾病的方法 |
| US20220304979A1 (en) * | 2019-12-17 | 2022-09-29 | Chinook Therapeutics, Inc. | Methods of reducing disease flares |
| CR20230083A (es) | 2020-07-10 | 2023-05-16 | Astrazeneca Ab | Combinación de zibotentan y dapagliflozina para el tratamiento de la enfermedad renal crónica |
| CN120302971A (zh) | 2022-10-28 | 2025-07-11 | 奇努克治疗公司 | 使用内皮素受体拮抗剂和april结合抗体治疗iga肾病 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US7208517B1 (en) * | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
| US6946481B1 (en) | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| US7365093B2 (en) | 1994-08-19 | 2008-04-29 | Abbott Laboratories | Endothelin antagonists |
| US5767144A (en) | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
| US6162927A (en) | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
| DE69527072T2 (de) * | 1994-08-19 | 2003-02-13 | Abbott Laboratories, Abbott Park | Endothelin antagoniste |
| US6124341A (en) | 1996-02-13 | 2000-09-26 | Abbott Laboratories | Endothelin antagonists |
| US5801250A (en) | 1996-12-13 | 1998-09-01 | Abbott Laboratories | Process for the stereoselective production of nitro-enamine compounds |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| JP2002524546A (ja) | 1998-09-14 | 2002-08-06 | アボット・ラボラトリーズ | 立体選択性ニトロ化合物の製造方法 |
| US20020055457A1 (en) | 2000-08-07 | 2002-05-09 | Janus Todd J. | Methods of treating cancer and the pain associated therewith using endothelin antagonists |
| WO2002017912A1 (en) * | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Endothelin antagonists |
| US20030022811A1 (en) | 2001-04-11 | 2003-01-30 | Amitabh Singh | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| US20030092757A1 (en) | 2001-04-11 | 2003-05-15 | Amitabh Singh | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| UA79248C2 (en) * | 2001-11-09 | 2007-06-11 | Janssen Pharmaceutica Nv | Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| WO2006034234A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 3 of atrasentan hydrochloride |
| US20060189675A1 (en) | 2004-09-17 | 2006-08-24 | Steve King | Crystalline form of a drug |
| US20060135596A1 (en) * | 2004-09-17 | 2006-06-22 | Zhang Geoff G | Amorphous form of a drug |
| US20060063825A1 (en) * | 2004-09-17 | 2006-03-23 | Walter Dziki | Crystalline form of a drug |
| US20080132710A1 (en) | 2006-12-04 | 2008-06-05 | Abbott Laboratories | Atrasentan hydrochloride crystalline form 2 |
| EP2294047A2 (en) * | 2008-04-04 | 2011-03-16 | Actavis Group PTC EHF | Novel mandelate salt of fesoterodine |
| US20100184026A1 (en) | 2009-01-22 | 2010-07-22 | Abbott Laboratories | Companion Diagnostic Assays For Endothelin Receptor Antagonists |
-
2013
- 2013-12-18 US US14/133,297 patent/US8962675B1/en active Active
-
2014
- 2014-09-10 AU AU2014318924A patent/AU2014318924A1/en not_active Abandoned
- 2014-09-10 CN CN201480061886.9A patent/CN105745204A/zh active Pending
- 2014-09-10 EP EP14780663.2A patent/EP3044222B1/en not_active Not-in-force
- 2014-09-10 WO PCT/US2014/054888 patent/WO2015038571A1/en not_active Ceased
- 2014-09-10 JP JP2016542052A patent/JP2016530311A/ja active Pending
- 2014-09-10 CA CA2923627A patent/CA2923627C/en active Active
- 2014-09-10 MX MX2016003065A patent/MX2016003065A/es unknown
- 2014-09-10 EP EP17172157.4A patent/EP3239148A1/en not_active Withdrawn
-
2015
- 2015-01-12 US US14/594,742 patent/US9637476B2/en active Active
-
2016
- 2016-03-11 CL CL2016000583A patent/CL2016000583A1/es unknown
-
2017
- 2017-03-21 US US15/464,455 patent/US20170190692A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530311A5 (enExample) | ||
| JP2018024682A5 (enExample) | ||
| JP2016000739A5 (enExample) | ||
| JP2017522276A5 (enExample) | ||
| JP2012521994A5 (enExample) | ||
| JP2016503010A5 (enExample) | ||
| JP2015535287A5 (enExample) | ||
| JP2013199502A5 (enExample) | ||
| RU2012138892A (ru) | СОЛИ И ПОЛИМОРФЫ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5,-ТЕТРАГИДРО-6Н-АЗЕПИНО[5,4,3-cd]ИНДОЛ-6-ОНА | |
| RU2015106137A (ru) | Кристаллический полиморф 4-[5-(пиридин-4-ил)-1н-1,2,4-триазол-3-ил]-пиридин-2-карбонитрила и способ его получения | |
| JP2009235086A5 (enExample) | ||
| JP2009502963A5 (enExample) | ||
| JP2015532645A5 (enExample) | ||
| JP2014524442A5 (enExample) | ||
| JP2012176975A5 (enExample) | ||
| JP2012001634A5 (enExample) | ||
| JP2014097964A5 (enExample) | ||
| JP2009531465A5 (enExample) | ||
| JP2013075773A5 (enExample) | ||
| RU2008141373A (ru) | Соль алискирена и серной кислоты | |
| RU2016141650A (ru) | Амидные соединения | |
| JP2013028864A5 (ja) | 銀ナノ粒子を製造するプロセスおよび導電性要素を製造するプロセス | |
| JP2012054542A5 (ja) | トリアゾール誘導体および複素環化合物 | |
| JP2013538849A5 (enExample) | ||
| JP2013523706A5 (enExample) |